{
    "clinical_study": {
        "@rank": "139795", 
        "brief_summary": {
            "textblock": "RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor\n      cells and slow the growth of kidney cancer.\n\n      PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have\n      recurrent or stage IV kidney cancer."
        }, 
        "brief_title": "ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer", 
        "completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate in patients with progressive stage IV or recurrent renal\n           cell cancer treated with ZD 1839.\n\n        -  Determine the median time to objective progression in these patients receiving this\n           drug.\n\n        -  Determine the toxic effects of this drug in this patient population.\n\n        -  Determine if epidermal growth factor receptor expression in tumor tissue correlates\n           with response and survival of these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral ZD 1839 daily. Courses repeat every 28 days in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients are followed every 8 weeks.\n\n      PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 11-23\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed stage IV or recurrent renal cell carcinoma\n             not amenable to potentially curative surgery\n\n          -  Evidence of disease progression\n\n          -  Measurable disease\n\n               -  At least 20 mm with conventional techniques OR\n\n               -  At least 10 mm with spiral CT scan\n\n          -  No brain metastases\n\n          -  Malignant tissue available\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 2 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Other:\n\n          -  No prior allergy to compounds of similar chemical or biologic composition to ZD 1839\n\n          -  No ongoing or active infection\n\n          -  No other uncontrolled illness or psychiatric condition that would preclude study\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No more than 2 prior immunotherapy (interferon alfa or interleukin-2) regimens\n\n          -  At least 4 weeks since prior immunotherapy and recovered\n\n          -  No concurrent immunotherapy\n\n        Chemotherapy:\n\n          -  No more than 1 prior chemotherapy regimen\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No prior therapy for metastatic disease\n\n          -  No other concurrent investigational agents\n\n          -  No concurrent oral retinoids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014183", 
            "org_study_id": "CDR0000068512", 
            "secondary_id": [
                "MSGCC-0044", 
                "NCI-1639"
            ]
        }, 
        "intervention": {
            "intervention_name": "gefitinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "September 23, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSGCC-0044"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Marlene & Stewart Greenebaum Cancer Center, University of Maryland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Veterans Affairs Medical Center - Baltimore"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent", 
        "overall_official": {
            "affiliation": "University of Maryland Greenebaum Cancer Center", 
            "last_name": "Nancy A. Dawson, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014183"
        }, 
        "responsible_party": {
            "organization": "UM Greenebaum Cancer Center"
        }, 
        "source": "University of Maryland", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Maryland Greenebaum Cancer Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Maryland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2009"
    }, 
    "geocoordinates": {
        "Marlene & Stewart Greenebaum Cancer Center, University of Maryland": "39.29 -76.612", 
        "Veterans Affairs Medical Center - Baltimore": "39.29 -76.612"
    }
}